TRANSDERMAL ESTRADIOL THERAPY FOR PROSTATE CANCER REDUCES THROMBOPHILIC ACTIVATION AND PROTECTS AGAINST THROMBOEMBOLISM

These results suggest that transdermal estradiol reduces thrombophilic activation in men with advanced prostate cancer, and protects against the risk of thrombosis.